A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC
Trial details
- Registry ID
- NCT04262804
- Phase
- Phase 2
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBCNCT04262804 | Zai Lab (Shanghai) Co., Ltd. | Phase 2 | Unknown | 2021-09-03Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |